GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (NAS:VRDN) » Definitions » Goodwill

VRDN (Viridian Therapeutics) Goodwill : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Viridian Therapeutics Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Viridian Therapeutics's goodwill for the quarter that ended in Sep. 2024 was $0.00 Mil.


Viridian Therapeutics Goodwill Historical Data

The historical data trend for Viridian Therapeutics's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics Goodwill Chart

Viridian Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Goodwill
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Viridian Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Viridian Therapeutics Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.


Viridian Therapeutics  (NAS:VRDN) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Viridian Therapeutics's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill-to-Asset (A: Dec. 2023 )=Goodwill/Total Assets
=0/490.424
=0.00

Viridian Therapeutics's Goodwill-to-Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Goodwill-to-Asset (Q: Sep. 2024 )=Goodwill/Total Assets
=0/771.9
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Viridian Therapeutics Goodwill Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.


Viridian Therapeutics Business Description

Traded in Other Exchanges
Address
221 Crescent Street, Suite 401, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Executives
Thomas W. Beetham officer: Chief Operating Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Stephen F. Mahoney director, officer: President and CEO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Fairmount Healthcare Fund Ii Gp Llc director, other: See Remarks 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Gp Llc director, other: See Remarks 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Sarah Gheuens director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Seth Harmon officer: See Remarks C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 401, WALTHAM MA 02453
Lara Meisner officer: General Counsel and Secretary C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG. 17, SUITE 102, WALTHAM MA 02453
Scott Dunseth Myers director, officer: Chief Executive Officer C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Jonathan Violin officer: President and COO 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Barrett Katz officer: Chief Medical Officer 6200 LOOKOUT ROAD, C/O MIRAGEN THERAPEUTICS, INC., BOULDER CO 80301
Carrie Melvin officer: COO C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG 17, SUITE 102B, WALTHAM MA 02453
Frazier Life Sciences Public Fund, L.p. 10 percent owner TWO UNION SQUARE, 601 UNION ST., SUITE 3200, SEATTLE WA 98101
Fhmlsp, L.l.c. 10 percent owner C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
L.p. Fhmlsp, 10 percent owner C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Kristian Humer officer: CFO and CBO C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301